 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
2006 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Al Za’abi MA (1), Xiaonian X (2), Donovan T (3), Charles BG (1) | Use of Routine Data for Determination of the Population Pharmacokinetics and Enteral Bioavailability of Phenytoin in Neonates and Infants with Seizures | 3/27/2006 4:07:15 AM | Poster: Applications- CNS |
Detecting a gene effect in pharmacokinetic models: comparison of different methods | 3/31/2006 11:12:35 AM | Poster: Methodology- Other topics | |
Efficient Sampling Windows for Parameter Estimation in Population Models | 3/28/2006 6:36:16 PM | Poster: Methodology- Design | |
Boström, Emma, Ulrika S. H. Simonsson and Margareta Hammarlund-Udenaes | In vivo blood-brain barrier transport of oxycodone in the rat – active influx and implications for PK/PD | 3/28/2006 4:43:23 PM | Poster: Applications- CNS |
Are population PK/PD models adequately evaluated? An exhaustive survey of the literature between 2002 and 2004 | 3/31/2006 5:29:30 PM | Oral Presentation: Model Building Session | |
Prins, K (1), B. Poland (1), V. Nicolas (2), H. Porchet (2), P. Scalfaro (2), R. Bruno (1) | Modeling and Simulation of DEBIO-025 to Support Design of a Dose-Response Monotherapy Study in HIV-1 infected Patients | 3/27/2006 12:06:27 PM | Poster: Applications- Anti-infectives |
Claret, L. (1), P. Girard (2), K.P. Zuideveld(3), K. Jorga (3), J. Fagerberg (3), R. Bruno (1) | A longitudinal model for tumor size measurements in clinical oncology studies | 3/31/2006 3:46:45 PM | Poster: Applications- Oncology |
Bias and Uncertainty of Monte Carlo Simulations with Beta-Lactams | 3/29/2006 9:29:24 PM | Poster: Applications- Anti-infectives | |
Carlsson, Kristin C., Radojka M. Savic, Andrew Hooker, Mats O. Karlsson. | Mixture models in NONMEM - how to find the individual probability of belonging to a specific mixture, and why this can be useful information | 3/27/2006 3:57:37 PM | Poster: Methodology- Other topics |
Pharmacokinetic variability of the absorption of enoxaparin used subcutaneously for venous thromboembolism prophylaxis | 3/30/2006 9:47:16 PM | Poster: Applications- Coagulation | |
Therapeutic modelling and analysis of random feeding features of feed-administered chlortetracycline | 4/11/2006 11:23:34 AM | Poster: Applications- Anti-infectives | |
Population pharmacokinetics of Valganciclovir in solid organ transplant recipients infected by cytomegalovirus | 3/31/2006 6:54:50 PM | Poster: Applications- Anti-infectives | |
Analysis of digoxin data using Non-Parametric Maximum Likelihood (NPML) | 3/31/2006 5:38:32 PM | Poster: Methodology- Algorithms | |
Modelling of insulin secretion: from beta-cell physiology to sulphonylurea-mediated insulin secretion | 3/27/2006 3:35:22 PM | Poster: Applications- Endocrine | |
Comparison of models for baseline | 3/29/2006 7:05:44 PM | Poster: Methodology- Model evaluation | |
How is model building reported for population PK-PD? An exhaustive survey of the literature between 2002 and 2004 | 3/31/2006 2:19:57 PM | Oral Presentation: Model Building Session | |
Dehez, Marion(1)(2)(3), Marylore Chenel(1), Roeline Jochemsen(1), Stéphanie Ragot(2) | Population modeling approach of circadian blood pressure variations using ambulatory monitoring in dippers and non dippers | 3/31/2006 10:04:26 AM | Poster: Applications- Other topics |
GastroPlus | 5/17/2006 12:28:23 PM | Software demonstration | |
Dodds, M.G. (1), J.E. Visich(1), I. Nestorov(1), R. Overgaard(2), M.C. Rogge(1) | Population pharmacodynamic model of the effects of recombinant human interleukin 21 on platelets in humans | 3/31/2006 11:45:11 PM | Poster: Applications- Oncology |
Direct application of Bayes theorem for the combination of population pharmacokinetic analyses. | 3/29/2006 6:25:57 PM | Poster: Methodology- Other topics | |
Bayesian Estimation of Optimal Sampling Times for Pharmacokinetic Models | 3/21/2006 11:44:49 PM | Poster: Methodology- Design | |
Edginton, A.N.(1), S. Willmann (1), Sevestre, M (2), Kirchheiner, J (3) | Determining the effect of CYP2C9 genotypes on diclofenac metabolism using individualized coupled physiology-based pharmacokinetic modeling | 3/31/2006 2:05:47 PM | Oral Presentation: Applications |
Use of a physiology-based whole-body population model to simulate the influence of anthropometric-, clearance-, and physiological-variance on the pharmacokinetics of drugs | 3/31/2006 1:59:20 PM | Poster: Methodology- PBPK | |
Elsherbiny, D.(1), S. Asimus(2), M.O. Karlsson(1), M. Ashton(2), U. S. H. Simonsson(1) | Modeling of the induction of CYP2B6 and CYP2C19 by artemisinin antimalarials | 3/15/2006 12:13:39 PM | Oral Presentation: Applications |
Hands-On Demonstration of PDx-Pop® v2.0; Tools for Expediting Population Analysis | 5/13/2006 8:49:51 AM | Software demonstration | |
Friberg, Lena E.(1), An M. Vermeulen(2), Mats O. Karlsson(1) | A mechanism-based pharmacokinetic-pharmacodynamic model of the time-course of prolactin following antipsychotic drug treatment | 3/20/2006 8:49:25 PM | Poster: Applications- CNS |
Comparison of conventional In Vitro - In Vivo Correlation methodology with non-linear mixed effects modelling | 3/27/2006 1:59:59 PM | Poster: Methodology- Other topics | |
R/NONMEM Toolbox for Simulation from Posterior Parameter (Uncertainty) Distributions | 3/27/2006 10:36:26 PM | Poster: Methodology- Algorithms | |
Model-Based Drug Development: Optimization of AQUAVAN® Injection Dosing for Minimal-to-Moderate Sedation | 3/27/2006 10:58:10 PM | Oral Presentation: Applications | |
Grasela, Thaddeus(1), Jill Fiedler-Kelly(1), Cynthia Walawander(1), Charles W. Dement(2) | Challenges in the Transition to Model-Based Development | 3/2/2006 4:44:37 PM | Oral Presentation |
Optimizing Fluconazole Dosing in Preterm Neonates Based on Simulations from Posterior Parameter (Uncertainty) Distributions | 3/31/2006 9:20:46 PM | Poster: Applications- Anti-infectives | |
Monte Carlo Parametric Expectation Maximization (MC-PEM) Method for Analyzing Population Pharmacokinetic/ Pharmacodynamic (PK/PD) Data | 1/14/2006 7:59:24 PM | Oral Presentation: Methodology | |
The PDX-MC-PEM software | 5/5/2006 9:16:43 AM | Software demonstration | |
A Population Model Describing the Activity-time Course of Pegylated Asparaginase in Children | 3/31/2006 4:10:08 PM | Poster: Applications- Oncology | |
A KPD Model for ordered categorical data: application to toxicity score in colorectal cancer patients treated with capecitabine | 3/9/2006 2:49:46 PM | Oral Presentation: Lewis Sheiner Student Session | |
Paediatric population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in cystic fibrosis and bone marrow transplant patients | 3/30/2006 9:49:16 AM | Poster: Applications- Anti-infectives | |
A D-optimal designed population pharmacokinetic study of itraconazole capsules and solution in adults with cystic fibrosis | 1/16/2006 8:24:01 AM | Poster: Methodology- Design | |
Population PK/PD Modelling & Simulation of Hematological Toxicity of Trabectedin in Cancer Subjects | 3/31/2006 9:13:49 PM | Poster: Applications- Oncology | |
NONMEM Termination Status is Not an Important Indicator of the Quality of Bootstrap Parameter Estimates | 3/31/2006 11:27:23 AM | Poster: Methodology- Model evaluation | |
Conditional weighted residuals, an improved model diagnostic for the FO/FOCE methods. | 3/31/2006 2:57:34 PM | Oral Presentation: Stuart Beal Methodology Session | |
An extension of the indirect response models to ordered categorical pharmacodynamic data using latent variables | 3/31/2006 8:19:10 PM | Poster: Methodology- Other topics | |
Hutmacher, Matthew M , Anand Vidyashankar, and Debu Mukherjee | Model Selection Using the Minimum Hellinger Distance Criterion (MHDC) with an Introduction to Minimum Hellinger Distance Estimation (MHDE) | 3/31/2006 8:14:29 PM | Oral Presentation: Stuart Beal Methodology Session |
Jelliffe, R., A Schumitzky, D Bayard, R Leary, M Van Guilder, A Gandhi, M Neely, and A Bustad. | The USC*PACK BigWinPops and MM-USCPACK Software | 4/28/2006 3:36:13 AM | Software demonstration |
Epirubicin pharmacokinetics-pharmacodynamics and metabolic pathway-associated gene polymorphisms: Significant influence of the novel UDP-glucuronosyltransferase 2B7 promoter mutation -66T>C | 2/27/2006 11:01:41 AM | Poster: Applications- Other topics | |
Mechanism-based pharmacokinetic and pharmacodynamic modelling of tesaglitazar in type 2 diabetes patients | 3/28/2006 1:23:34 PM | Poster: Applications- Endocrine | |
Overview of oral absorption models and modelling issues | 5/16/2006 9:20:10 AM | Oral Presentation | |
Plock, N.(1), C. Buerger(1), K. Kuester(1), C. Joukhadar(2), S. Kljucar(3), C. Kloft(1,4) | A Population Pharmacokinetic Model for the Simultaneous Description of Linezolid Tissue and Plasma Disposition in Healthy Volunteers and Septic Patients | 1/16/2006 1:46:04 PM | Poster: Applications- Anti-infectives |
A Modeling and Simulation Case Study: Impact on an Early Clinical Development Program | 3/20/2006 3:17:11 PM | Oral Presentation: Applications | |
Population Pharmacokinetic Analysis for Matuzumab (EMD 72000) – A Humanised EGFR-Targeted Monoclonal Antibody | 3/30/2006 11:13:36 AM | Poster: Applications- Oncology | |
New Insights into the Most Commonly Studied Drug Interaction with Antibiotics: Pharmacokinetic Interaction between Ciprofloxacin, Gemifloxacin and Probenecid at Renal and Non-renal Sites | 1/15/2006 4:08:29 AM | Poster: Applications- Anti-infectives | |
Langdon G (1), Gueorguieva I (2), Aarons L (3), Karlsson MO (1) | Linking preclinical and clinical whole body physiologically-based pharmacokinetic models with prior distributions in NONMEM | 3/27/2006 3:15:46 PM | Poster: Methodology- PBPK |
Analysing population PK/PD data with the MONOLIX software | 3/31/2006 6:59:35 AM | Software demonstration | |
Parallel Processing for Nonlinear Mixed Effects Modeling | 3/30/2006 8:37:36 PM | Poster: Methodology- Algorithms | |
Population pharmacokinetics of NS2330 and its major metabolite in Alzheimer’s disease patients | 3/31/2006 8:24:11 AM | Poster: Applications- CNS | |
Efficacy modelling of NS2330 in mild Alzheimer’s disease patients | 3/31/2006 8:22:17 AM | Poster: Applications- CNS | |
Zeumer, D., A. Staab, T. Lehr, C. Tillmann, K.-H. Liesenfeld, H. G. Schaefer | PROPHET - A convenient and efficient environment for the use of NONMEM in a global pharmaceutical company | 3/31/2006 10:37:26 AM | Poster: Methodology- Other topics |
Lindbom, Lars(1), Justin J Wilkins(1), Nicolas Frey(2), Mats O Karlsson(1), E Niclas Jonsson(1,2) | Evaluating the evaluations: resampling methods for determining model appropriateness in pharmacometric data analysis | 3/31/2006 2:07:40 PM | Poster: Methodology- Model evaluation |
Lopez-Pintor E (1), Valenzuela B (1), Montesinos A (2), Martín-Villodre A (2), Casabó V.G (2) | Population pharmacokinetics approach for salbutamol sulphate in rats | 3/31/2006 1:12:03 PM | Poster: Applications- Other topics |
Lovern, Mark R , Ginny Schmith, George Dukes, David McSorley | Using a Placebo Response Model to Optimize Clinical Trial Designs for Irritable Bowel Syndrome (IBS) Therapies | 3/30/2006 7:30:41 PM | Poster: Applications- Other topics |
Marshall, Scott1, Mike K Smith1, Eugene Cox2,3 and Jaap Mandema2,4 | Application of PK/PD modelling in the development eletriptan DR for the treatment of acute migraine and prevention of headache recurrence. | 3/31/2006 4:27:31 PM | Poster: Applications- CNS |
Pharmacokinetics of a single bolus of propofol in Chinese children of different ages | 3/9/2006 4:53:04 PM | Poster: Applications- CNS | |
A population pharmacokinetic model for s-warfarin: application of a mixture model to determine genotype/phenotype. | 3/30/2006 4:05:41 PM | Poster: Methodology- Model evaluation | |
Comparision of Pregabalin and Gabapentin Pharmacodynamics in Patients with Refractory Partial Seizures. | 3/20/2006 8:55:53 PM | Poster: Applications- CNS | |
Mills, Richard (1,2), Kayode Ogungbenro (1) & Leon Aarons (1) | Simultaneous fitting of the Minimal Model to IVGTT and Glucose Clamp Data | 3/23/2006 12:54:23 PM | Poster: Applications- Endocrine |
Acknowledging Parameter Uncertainty in the Simulation-Based Design of an Actinomycin-D Pharmacokinetic Study in Pediatric Patients with Wilms’ Tumor or Rhabdomyosarcoma | 3/16/2006 1:35:57 AM | Oral Presentation: Applications | |
A simple physiological-pharmacokinetic model to simulate bioequivalence trials | 4/4/2006 9:08:52 PM | Poster: Methodology- Model evaluation | |
Fernández-Teruel C, Navarro-Fontestad MC, González-Álvarez I, Bermejo M, Casabo VG | Sparse sampling designs: a new method for estimating the complete AUC and its standard error | 3/31/2006 6:59:09 PM | Poster: Methodology- Algorithms |
Nestorov, I.1, A. Munafo2, O. Papasouliotis2, J. Visich1 and M. Rogge1 | Population modeling of the relationship between TACI Ig exposure and biomarker response in patients with rheumatoid arthritis (RA) | 3/31/2006 8:04:03 PM | Poster: Applications- Biologicals/vaccines |
Population Pharmacokinetics of Gentamicin in Preterm and Term Newborn Infants | 4/20/2006 3:55:41 PM | Poster: Applications- Anti-infectives | |
Using the Lasso to simultaneously identify the covariate and variance-covariance structures of nonlinear mixed-effects models | 3/31/2006 2:29:48 PM | Poster: Methodology- Algorithms | |
Concentration-response analysis of antipsychotic drug effects using an indirect response model | 3/31/2006 2:02:02 PM | Poster: Applications- CNS | |
Non-Linear Population Pharmacokinetic Model for Otamixaban in Healthy Male Subjects | 3/31/2006 3:34:08 PM | Poster: Applications- Coagulation | |
Extension of the SAEM algorithm for the estimation of Inter-Occasion Variability: application to the population pharmacokinetics of nelfinavir and its metabolite M8 | 3/27/2006 10:38:38 AM | Poster: Methodology- Algorithms | |
Optimizing the Design of Phase I Studies of Erythropoietin Receptor Agonist Through Mechanism-Based PK/PD Modeling and Simulation | 4/3/2006 4:15:38 PM | Poster: Applications- Biologicals/vaccines | |
Marchand, M. (1), O. Petricoul (1), E. Fuseau (1), D. Bentley (2), D. Critchley (2) | Extrapolation from preclinical PKPD data to clinical response, Application to a new antiepileptic medication (drug X) | 3/24/2006 6:44:53 PM | Poster: Applications- CNS |
Transforming a set of office computers to a computing cluster. | 4/14/2006 9:11:12 PM | Software demonstration | |
Post, T.M.(1), J.I. Freijer (1), W. de Winter (1), B.A. Ploeger (1,2) | Accurate Interpretation of the Visual Predictive Check in order to Evaluate Model Performance | 3/30/2006 3:31:49 PM | Poster: Methodology- Model evaluation |
Mango Solutions | 5/15/2006 11:45:21 AM | Software demonstration | |
A simultaneous analysis of the time course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic model | 3/31/2006 9:43:18 PM | Poster: Applications- Oncology | |
Semi-mechanistic KPD model for haematological toxicity in breast cancer patients receiving high dose of chemotherapy | 4/3/2006 9:16:12 PM | Poster: Applications- Oncology | |
Bayesian Hierarchical Modeling of Receptor Occupancy in PET Trials | 3/24/2006 10:36:03 AM | Oral Presentation: Model Building Session | |
Pre-Clinical PK/PD Modeling for a Dipeptidyl Peptidase-IV Inhibitor | 3/30/2006 10:13:36 PM | Poster: Applications- Endocrine | |
Retout, Sylvie, Emmanuelle Comets, Hervé Le Nagard and France Mentré | New features for population designs evaluation and optimisation in R: PFIM 2.0 and PFIMOPT 2.0 | 3/31/2006 4:18:09 PM | Software demonstration |
Ribbing, J. (1), J. Nyberg (1), O. Caster (1), E.N. Jonsson (1,2) | The LASSO - A Novel Method for Predictive Covariate Model Building in Nonlinear Mixed Effects Models | 3/15/2006 2:12:37 PM | Oral Presentation: Methodology |
Rodrigues, C.L. (1) , I. Gueorguieva (2), Marylore Chenel (3), D. A. Berk (4) and L. Aarons (1) | Norfloxacin – a whole body physiologically based pharmacokinetic model | 3/30/2006 3:54:28 PM | Poster: Methodology- PBPK |
Complications in assessing the hepatic first-pass component of bioavailability | 5/18/2006 10:27:15 AM | Oral Presentation | |
Djebli, Nassim 1, Pierre Marquet1,2, Yann Le Meur1,3, Annick Rousseau1,4 | Population pharmacokinetics of sirolimus in adult renal transplant patients and Bayesian estimation of individual systemic exposure | 3/30/2006 6:14:31 PM | Poster: Applications- Other topics |
Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in paediatric renal transplant recipients using a non-parametric approach. | 3/31/2006 6:04:21 PM | Poster: Applications- Other topics | |
Simcyp - a platform for simulation and prediction of in vivo drug disposition in virtual human populations | 5/17/2006 11:45:19 PM | Software demonstration | |
Is it possible to perform equivalent simulations with NONMEM and TS2? | 3/31/2006 3:30:50 PM | Poster: Methodology- Other topics | |
Optimizing Dose Selection With Respect to Multiple Safety/Efficacy Endpoints Using Clinical Utility Concepts | 3/9/2006 12:47:50 AM | Oral Presentation: Applications | |
Samson, Adeline (1), Marc Lavielle (2) and France Mentré (1) | The SAEM algorithm for non-linear mixed models with left-censored data and differential systems: application to the joint modeling of HIV viral load and CD4 dynamics under treatment | 3/15/2006 12:28:22 PM | Oral Presentation: Lewis Sheiner Student Session |
Hussein, Ziad(1), Brigitte Lacroix(2), Maria-Laura Sargentini-Maier(2) | Population pharmacokinetics of the new antiepileptic drug brivaracetam | 4/20/2006 5:36:37 PM | Poster: Applications- CNS |
Evaluation of the nonparametric estimation method in NONMEM VI beta | 3/15/2006 4:17:22 PM | Oral Presentation: Stuart Beal Methodology Session | |
The likelihood ratio test appears robust to most residual error model misspecifications | 3/28/2006 12:59:03 PM | Poster: Methodology- Model evaluation | |
PKPD model for cathepsin K inhibition with balicatib and changes in bone turnover biomarkers, in particular NTx | 3/31/2006 7:15:37 PM | Poster: Applications- Endocrine | |
Population pharmacokinetics of balicatib, a cathepsin K inhibitor | 3/31/2006 7:11:38 PM | Poster: Applications- Endocrine | |
Tajima, Takeshi(1), Akihiro Yokoi (1), Peiming Ma (2), Ryosei Kawai (1) | Population approach to assess the relationship of cyclosporin exposure and renal dysfunction in Japanese patients with rheumatoid arthritis | 3/1/2006 6:53:13 AM | Poster: Applications- Other topics |
Development of a tool to simulate intra-individual variability encountered in animals from standard preclinical toxicological study | 3/14/2006 10:33:04 AM | Poster: Methodology- Design | |
Cystatin C as a new covariate to predict the renal elimination of drugs | 2/17/2006 5:05:56 PM | Oral Presentation: Applications | |
Tousset, E.(1), H. Figueiredo (2),M.P. Schneider(2),O. Bugnon(2), B.Vrijens (1) | Relation between patients’ variable compliance and office blood pressure in treatment-resistant hypertension. | 3/31/2006 4:28:09 PM | Poster: Methodology- Other topics |
Lindbom, L.(1), K. Tunblad(1), L. McFadyen(2), E.N. Jonsson(1), S. Marshall(2), M. O. Karlsson(1) | The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data | 3/27/2006 10:00:56 PM | Poster: Applications- CVS |
Population Pharmacokinetic-Pharmacodynamic modelling of olanzapine effects on the electroencephalogram in healthy volunteers. | 3/31/2006 9:41:59 AM | Poster: Applications- CNS | |
Model building and model parameter identification for transfer of dioxin TEQs from feed to eggs. | 2/7/2006 8:41:39 AM | Oral Presentation: Model Building Session | |
van Hest, Reinier1, Teun van Gelder1,2, Arnold Vulto1, Leslie Shaw3, Ron Mathôt1 | Pharmacokinetic modeling of plasma protein binding of mycophenolic acid in renal transplant recipients | 3/8/2006 10:37:14 AM | Poster: Applications- Other topics |
Mixed models for the analysis of categorical repeated measures | 3/9/2006 3:31:45 PM | Tutorial | |
Viberg, Anders (1), Otto Cars (2), Mats O. Karlsson (1) and Siv Jönsson (3) | Individualization of Cefuroxime Dosage using Pharmacodynamic targets, MIC distributions and Minimization of a Risk Function | 3/30/2006 3:43:58 PM | Oral Presentation: Applications |
The Population Approach Identity Crisis: The Search For Innovation In Modeling And Simulation | 3/21/2006 2:09:59 PM | Oral Presentation | |
Vicini, Paolo and the Resource Facility for Population Kinetics (RFPK) | The System for Population Kinetics (SPK) | 5/4/2006 8:30:40 AM | Software demonstration |
iClinical: NONMEM Workbench | 3/31/2006 7:45:08 PM | Software demonstration | |
Vis, Peter (1), Vanitha Sekar (2), Erno van Schaick (1) and Richard Hoetelmans (3) | Development and application of a population pharmacokinetic model of TMC114 in healthy volunteers and HIV-1 infected subjects after administration of TMC114 in combination with low dose ritonavir | 3/29/2006 12:41:45 PM | Poster: Applications- Anti-infectives |
An Adaptive Dosing Tool For Etoposide Using Neutrophil Counts Based on a Semi-Physiological Model | 3/29/2006 3:46:14 PM | Poster: Applications- Oncology | |
Population Analysis of Maraviroc Phase 1 Noncompartmental Pharmacokinetic Data | 4/6/2006 6:39:36 PM | Poster: Methodology- Other topics | |
Wilkins, Justin J (1), Hooker, Andrew (1), Karlsson, Mats O (1), Jonsson, E Niclas (2) | Xpose – an R-based population pharmacokinetic/pharmacodynamic model-building aid for NONMEM | 4/13/2006 2:46:03 PM | Software demonstration |
Wilkins, Justin J (1), Karlsson, Mats O (1), Jonsson, E Niclas (2) | Patterns and power for the visual predictive check | 4/11/2006 11:36:25 AM | Poster: Methodology- Model evaluation |
Population pharmacokinetic study of methotrexate in patient with lymphoid malignancy | 2/15/2006 2:23:33 PM | Poster: Applications- Oncology | |
Willmann, Stefan, Andrea N. Edginton, Walter Schmitt, Marcus Kleine-Besten, and Jennifer B. Dressman | Simulating Oral Absorption with PK-Sim®: Methodology and Application Examples | 4/28/2006 5:17:27 PM | Oral Presentation |
Hands-On Demonstrations of the Physiology-Based Pharmacokinetic Software, PK-Sim® | 4/28/2006 5:15:17 PM | Software demonstration | |
Simulation of the Nonlinear PK of Gabapentin and Midazolam in Adult and Pediatric Populations | 3/31/2006 3:27:10 AM | Oral Presentation: Applications | |
Yim, Dong-Seok (1), Dong-Gun Lee, Su-Mi Choi, Wan-Shik Shin, Hyon-oh Lah(1) | Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea | 2/24/2006 5:24:13 AM | Poster: Applications- Anti-infectives |
Pharmacogenetically guided dosing of the anticancer agent indisulam normalizes the risk of severe hematological toxicity | 1/17/2006 2:20:46 PM | Poster: Applications- Oncology | |
Semi-mechanistic PK/PD model of indisulam in combination with capecitabine: a time-dependent pharmacokinetic interaction contributes to excessive hematological toxicity | 3/8/2006 10:25:15 AM | Oral Presentation: Lewis Sheiner Student Session |
